Peninsula Medical: an innovator in medical aesthetics

Video by Lin Songtao

Shenzhen-based Peninsula Medical is a national high-tech enterprise specializing in the research and development, manufacturing, and sales of advanced medical devices.

Founded in 2008 by Lei Xiaobing, the company focuses on developing therapies that use photonic and electronic technologies — ultrasound, radio frequency, laser, and others — to help people look more radiant and live healthier lives.

Originally established in Chongqing, Peninsula Medical made a strategic move in 2015 when it relocated its headquarters to Bao’an District, Shenzhen, a decision that proved pivotal for its growth.

Lei Xiaobing, founder of Peninsula Medical.  Photos by Lin Songtao

“Starting in 2015, we recognized that Shenzhen offered a richer talent pool and a highly concentrated supply chain, making it far more favorable for our industry compared to Sichuan-Chongqing and the Yangtze River Delta regions,” Lei noted. “We consolidated our R&D teams here to make the most out of local resources.”

Peninsula Medical leveraged decades of experience, learning from European and American peers to build its own R&D team. “In our early days, we relied heavily on Western technologies. Today, our devices are installed in all of America’s top 30 medical aesthetics clinics,” Lei stated. China’s vast and growing market has also fueled its growth.

Currently, the company’s primary international markets are the United States and Japan. The U.S. accounts for approximately half of the global medical aesthetics market, and Peninsula Medical’s equipment has been widely adopted by leading hospitals and large medical chains.

Staff members test the latest MFUS Ultrasonic System.

Peninsula Medical developed China’s first Class III certified ultrasonic therapy device, the MFUS Ultrasonic System, which is also the world’s first ultrasound cosmetic device approved by the National Medical Products Administration (NMPA).

Employing micro-point focusing technology combined with a large focal zone, the device precisely targets the superficial musculoaponeurotic system (SMAS) layer, superficial fat, and dermis to reduce wrinkles and tighten skin.

After more than four years of rigorous clinical trials in China, the device demonstrated an impressive 89.6% effectiveness rate within three months. It also maintained an impeccable safety record, with no reported nerve damage or adverse effects, Lei stated.

The company has also launched its fifth-generation Golden Microneedling device, dubbed Unicorn+. It is designed to treat a range of common skin issues, including acne scars, pigmentation, enlarged pores, and blackheads. The device delivers high-frequency energy through ultrafine microneedles at varying depths to stimulate collagen contraction and regeneration.

Compared with previous devices, this latest model boosts treatment effectiveness by 30% while reducing pain by 60%, greatly improving patient comfort and acceptance, according to Lei.

China’s medical aesthetics market has grown at an annual rate of 15-20% for over ten years, and Lei emphasized that the industry is evolving from disorder to maturity and standardization. Peninsula Medical actively engages in national policy development and regulation formulation, Lei said.